Cargando…

Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects

Lipoprotein (a) [Lp(a)] is a modified LDL particle with an additional apolipoprotein [apo(a)] protein covalently attached by a thioester bond. Multiple isoforms of apo(a) exist that are genetically determined by differences in the number of Kringle-IV type-2 repeats encoded by the LPA gene. Elevated...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmitz, Gerd, Orsó, Evelyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361722/
https://www.ncbi.nlm.nih.gov/pubmed/25708587
http://dx.doi.org/10.1007/s11789-015-0074-0
_version_ 1782361693975740416
author Schmitz, Gerd
Orsó, Evelyn
author_facet Schmitz, Gerd
Orsó, Evelyn
author_sort Schmitz, Gerd
collection PubMed
description Lipoprotein (a) [Lp(a)] is a modified LDL particle with an additional apolipoprotein [apo(a)] protein covalently attached by a thioester bond. Multiple isoforms of apo(a) exist that are genetically determined by differences in the number of Kringle-IV type-2 repeats encoded by the LPA gene. Elevated plasma Lp(a) is an independent risk factor for cardiovascular disease. The phenotypic diversity of familial Lp(a) hyperlipidemia [Lp(a)-HLP] and familial hypercholesterolemia [FH], as defined risks with genetic background, and their frequent co-incidence with additional cardiovascular risk factors require a critical revision of the current diagnostic and therapeutic recommendations established for isolated familial Lp(a)-HLP or FH in combination with elevated Lp(a) levels. Lp(a) assays still suffer from poor standardization, comparability and particle variation. Further evaluation of the current biomarkers and establishment of novel comorbidity biomarkers are necessary for extended risk assessment of cardiovascular disease in FH or Lp(a)-HLP and to better understand the pathophysiology and to improve patient stratification of the Lp(a) syndrome complex. Lp(a) promotes vascular remodeling, increased lesion progression and intima media thickening through induction of M1-macrophages, antiangiogenic effects (e.g. vasa vasorum) with secretion of the antiangiogenic chemokine CXCL10 (IP10) and CXCR3 mediated activation of Th1- and NK-cells. In addition inhibition of serine proteases causing disturbances of thrombosis/ hemostasis/ fibrinolysis, TGFb-activation and acute phase response (e.g. CRP, anti-PL antibodies) are major features of Lp(a) pathology. Anti-PL antibodies (EO6 epitope) also bind to oxidized Lp(a). Lipoprotein apheresis is used to reduce circulating lipoproteins in patients with severe FH and/or Lp(a)-HLP, particularly with multiple cardiovascular risks who are intolerant or insufficiently responsive to lipid-lowering drugs.
format Online
Article
Text
id pubmed-4361722
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-43617222015-03-20 Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects Schmitz, Gerd Orsó, Evelyn Clin Res Cardiol Suppl Article Lipoprotein (a) [Lp(a)] is a modified LDL particle with an additional apolipoprotein [apo(a)] protein covalently attached by a thioester bond. Multiple isoforms of apo(a) exist that are genetically determined by differences in the number of Kringle-IV type-2 repeats encoded by the LPA gene. Elevated plasma Lp(a) is an independent risk factor for cardiovascular disease. The phenotypic diversity of familial Lp(a) hyperlipidemia [Lp(a)-HLP] and familial hypercholesterolemia [FH], as defined risks with genetic background, and their frequent co-incidence with additional cardiovascular risk factors require a critical revision of the current diagnostic and therapeutic recommendations established for isolated familial Lp(a)-HLP or FH in combination with elevated Lp(a) levels. Lp(a) assays still suffer from poor standardization, comparability and particle variation. Further evaluation of the current biomarkers and establishment of novel comorbidity biomarkers are necessary for extended risk assessment of cardiovascular disease in FH or Lp(a)-HLP and to better understand the pathophysiology and to improve patient stratification of the Lp(a) syndrome complex. Lp(a) promotes vascular remodeling, increased lesion progression and intima media thickening through induction of M1-macrophages, antiangiogenic effects (e.g. vasa vasorum) with secretion of the antiangiogenic chemokine CXCL10 (IP10) and CXCR3 mediated activation of Th1- and NK-cells. In addition inhibition of serine proteases causing disturbances of thrombosis/ hemostasis/ fibrinolysis, TGFb-activation and acute phase response (e.g. CRP, anti-PL antibodies) are major features of Lp(a) pathology. Anti-PL antibodies (EO6 epitope) also bind to oxidized Lp(a). Lipoprotein apheresis is used to reduce circulating lipoproteins in patients with severe FH and/or Lp(a)-HLP, particularly with multiple cardiovascular risks who are intolerant or insufficiently responsive to lipid-lowering drugs. Springer Berlin Heidelberg 2015-02-24 2015 /pmc/articles/PMC4361722/ /pubmed/25708587 http://dx.doi.org/10.1007/s11789-015-0074-0 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Article
Schmitz, Gerd
Orsó, Evelyn
Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects
title Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects
title_full Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects
title_fullStr Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects
title_full_unstemmed Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects
title_short Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects
title_sort lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361722/
https://www.ncbi.nlm.nih.gov/pubmed/25708587
http://dx.doi.org/10.1007/s11789-015-0074-0
work_keys_str_mv AT schmitzgerd lipoproteinahyperlipidemiaascardiovascularriskfactorpathophysiologicalaspects
AT orsoevelyn lipoproteinahyperlipidemiaascardiovascularriskfactorpathophysiologicalaspects